Li Shao-dan, Yang Ming-hui, Liu Yi
Institute of Traditional Chinese Medicine, the PLA General Hospital, Beijing.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 May;31(5):622-5.
To observe the effect of Bushen Huoxue Granule (BHG) on dopamine (DA) neurotransmitter and dopamine transporter (DAT) in the brain of patients with Parkinson's disease (PD) as an adjunctive therapy.
Ninety-four PD patients were randomly assigned to two groups, 47 in each group. Madopar was given to all as the basic treatment group. The placebo was given to those in the control group while BHG was given to those in the treatment. The therapeutic course for all was three months. Before and after treatment DA levels in the brain of patients were detected by encephalofluctuograph (EFG) technique. Changes of DAT in the striatum of patients in the treatment group were detected by positron emission tomography (PET) and region of interest (ROI) analysis.
(1) Before treatment the DA level was lower in the two groups than the normal value, showing significant difference (P < 0.01), but with no significant difference between the two groups (P > 0.05). After treatment the DA level obviously increased in the two groups, showing significant difference from that before treatment (P < 0.01). No significant difference existed in the DA level in the two groups when compared with the normal value (P > 0.05), but with significant difference between the two groups (P < 0.05). Better results were obtained in the treatment group than in the control group. (2) The DAT radioactive accumulation inside the striatum increased obviously in the treatment group after treatment. ROI analysis showed the total ratio of striatum/cerebellum before and after treatment was 1.86 +/- 0.32 and 2.61 +/- 0.53 respectively, showing statistical difference (P < 0.05).
BHG could improve the DA level of PD patients, and increasing DAT contents in the striatum, thus playing a role in effectively treating PD.
观察补肾活血颗粒（BHG）作为辅助治疗对帕金森病（PD）患者脑内多巴胺（DA）神经递质及多巴胺转运体（DAT）的影响。
将94例PD患者随机分为两组，每组47例。所有患者均给予美多芭作为基础治疗组。对照组给予安慰剂，治疗组给予BHG。所有患者的疗程均为3个月。治疗前后采用脑涨落图（EFG）技术检测患者脑内DA水平。采用正电子发射断层扫描（PET）及感兴趣区（ROI）分析检测治疗组患者纹状体中DAT的变化。
（1）治疗前两组患者DA水平均低于正常值，差异有统计学意义（P < 0.01），但两组间差异无统计学意义（P > 0.05）。治疗后两组患者DA水平均明显升高，与治疗前比较差异有统计学意义（P < 0.01）。与正常值比较，两组患者DA水平差异无统计学意义（P > 0.05），但两组间差异有统计学意义（P < 0.05）。治疗组效果优于对照组。（2）治疗后治疗组纹状体内DAT放射性积聚明显增加。ROI分析显示，治疗前后纹状体/小脑的总比值分别为1.86±0.32和2.61±0.53，差异有统计学意义（P < 0.05）。
BHG可提高PD患者的DA水平，增加纹状体中DAT含量，从而有效治疗PD。
